The abstract is read at the publisher; the summary is JClub's.
MTAP-deleted advanced non-small cell lung cancer shows worse progression-free survival than MTAP wild-type on anti-PD-(L)1–based regimens, with hazard ratios up to 1.89.
- Why it matters: Outcomes for MTAPdel NSCLC treated with standard systemic therapies are poorly defined, limiting how clinicians interpret trial-relevant vulnerability to MTAP-targeting approaches.
- What they did: In a single-center retrospective cohort (Oct 2016–Mar 2024), 93 MTAPdel and 307 MTAPwt patients receiving systemic therapy were compared using tissue-based next-generation sequencing and multivariable PFS/OS analyses.
- The result: MTAPdel patients had shorter PFS on anti-PD-(L)1 monotherapy (HR 1.70, P = 0.040) and platinum doublet + anti-PD-(L)1 (HR 1.89, P = 0.006), while overall survival was similar across regimens.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.